Ryvu Therapeutics S.A. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was PLN 10.76 million compared to PLN 0.031 million a year ago. Revenue was PLN 15.03 million compared to PLN 7.3 million a year ago. Net loss was PLN 28.51 million compared to PLN 36.92 million a year ago. Basic loss per share from continuing operations was PLN 1.23 compared to PLN 2.01 a year ago. Diluted loss per share from continuing operations was PLN 1.23 compared to PLN 2.01 a year ago.
For the six months, sales was PLN 23.62 million compared to PLN 0.063 million a year ago. Revenue was PLN 33.35 million compared to PLN 14.09 million a year ago. Net loss was PLN 46.1 million compared to PLN 63.46 million a year ago. Basic loss per share from continuing operations was PLN 2.03 compared to PLN 3.46 a year ago. Diluted loss per share from continuing operations was PLN 2.03 compared to PLN 3.46 a year ago.